

Lara Perryman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10934102/publications.pdf>

Version: 2024-02-01

11
papers

698
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1676
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. <i>Cancers</i> , 2022, 14, 981.	3.7	3
2	An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. <i>Clinical and Translational Medicine</i> , 2021, 11, e572.	4.0	15
3	The lysyl oxidase like 2/3 enzymatic inhibitor, PXS153A, reduces crosslinks and ameliorates fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1759-1770.	3.6	76
4	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <i>Neoplasia</i> , 2017, 19, 684-694.	5.3	13
5	Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging. <i>NMR in Biomedicine</i> , 2016, 29, 1608-1617.	2.8	11
6	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1267-76.	7.1	31
7	Paediatric and adult malignant glioma: close relatives or distant cousins?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 400-413.	27.6	166
8	Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR α . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1407-1418.	4.1	45
9	MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature. <i>Cancer Research</i> , 2010, 70, 9243-9252.	0.9	152
10	Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development. <i>PLoS ONE</i> , 2009, 4, e5209.	2.5	102
11	EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines. <i>Clinical Cancer Research</i> , 2009, 15, 5753-5761.	7.0	84